References
- W. J. Roesler, J. G. Graham, R. Kolen, D. J. Klemm and P. J. Mc Fie, The cAMP response element binding protein synergies with other transcription factors to mediate cAMP responsiveness, J. Biol. Chem. 270 (1995) 8225-8232; DOI: 10.1074/jbc270.14.8225.
- G. S. McKnight, Cyclic AMP second messenger system, Curr. Opin. Cell Biol. 3 (1991) 213-217.10.1016/0955-0674(91)90141-K
- S. S. Taylor, S. A. Buechler and W. Yonemoto, cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes, Annu. Rev. Biochem. 59 (1990) 971-1005.
- R. W. Butcher and E. W. Sutherland, Adenosine 3,5-phosphate in biological materials. I. Purification and properties of cyclic 3,5-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3,5-phosphate in human urine, J. Biol. Chem. 237 (1962) 1244-1250.10.1016/S0021-9258(18)60316-3
- A. Hatzelmann, E. J. Morcillo, G. Lungarella, S. Adnot, S. Sanjar, R. Beume, C. Schudt and H. Tenor, The preclinical pharmacology of roflumilaste - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease, Pulm. Pharmacol. Ther. 23 (2010) 235-256; DOI: 10.1016/j.pupt.2010.03.011.10.1016/j.pupt.2010.03.01120381629
- W. Jiang, J. Guan, M. J. Macielag, S. Zhang, Y. Qiu, P. Kraft, S. Bhattacharjee, T. M. John, D. H. Johnson, S. Lundeen and Z. Sui, Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction, J. Med. Chem. 48 (2005) 2126-2133; DOI: 10.1021/jm0401098.10.1021/jm040109815771456
- A. Daugan, P. Grondin, C. Ruault, A. C. Le Monnier de Gouville, H. Coste, J. Kirilovsky, F. Hyafil and R. Labaudinière, The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-Tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3 (2H)-dione Analogues, J. Med. Chem. 46 (2003) 4525-4532; DOI: 10.1021/jm030056e.10.1021/jm030056e14521414
- A. Daugan, P. Grondin, C. Ruault, H. Coste, J. Kirilovsky, F. Hyafil and R. Labaudinière, The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 2: 2, 3, 6, 7, 12, 12a-hexahydropyrazino [1',2':1,6] pyrido[3,4-b] indole-1,4-dione analogues, J. Med. Chem. 46 (2003) 4533-4542; DOI: 10.1021/jm0300577.10.1021/jm030057714521415
- A. Martínez, A. Castro, C. Gil, M. Miralpeix, V. Segarra, T. Doménech, J. Beleta, J. M. Palacios, H. Ryder, X. Miró, C. Bonet, J. M. Casacuberta, F. Azorín, B. Piña and P. Puigdoménech, Benzyl derivatives of 2, 1, 3-benzo- and benzothieno [3,2-a] thiadiazine 2,2-dioxides: First phosphodiesterase 7 inhibitors, J. Med. Chem. 43 (2000) 683-689; DOI: 10.1021/jm990382n.10.1021/jm990382n10691694
- A. J. Duplantier, C. J. Andresen, J. B. Cheng, V. L. Cohan, C. Decker, F. M. DiCapua, K. G. Kraus, K. L. Johnson, J. W. Watson, R. T. Wester and A. S. Williams, 7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridines as novel inhibitors of human eosinophil phosphodiesterase, J. Med. Chem. 41 (1998) 2268-2277; DOI: 10.1021/jm9800090.10.1021/jm98000909632360
- D. P. Rotella, Z. Sun, Y. Zhu, J. Krupinski, R. Pongrac, L. Seliger, D. Normandin and J. E. Macor, N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction, J. Med. Chem. 43 (2000) 1257-1263. DOI: 10.1021/jm000081+.10.1021/jm000081+10753463
- D. P. Rotella, Z. Sun, Y. Zhu, J. Krupinski, R. Pongrac, L. Seliger, D. Normandin and J. E. Macor, Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors, J. Med. Chem. 43 (2000) 5037-5043; DOI: 10.1021/jm000336j.10.1021/jm000336j11150175
- A. A. Bekhit, N. S. Habib and A. El-Din, Synthesis and antimicrobial evaluation of chalcone and syndrome derivatives of 4(3H)-quinazolinone, Boll. Chim. Farm. 140 (2001) 297-301.
- B. Maggio, G. Daidone and D. Raffa, Synthesis and pharmacological study of ethyl 1-methyl-5-(substituted 3,4-dihydro-4-oxoquinazolin-3-yl)-1H-pyrazole-4-acetates, Eur. J. Med. Chem. 36 (2001) 737-742.10.1016/S0223-5234(01)01259-4
- B. Lasztoczi, R. Kovacs and L. Nyikos, A glutamate receptor subtype antagonist inhibits seizures in rat hippocampal slices, Neuroreport 13 (2002) 351-356.10.1097/00001756-200203040-0002011930136
- A. Lopez-Farre, J. A. Rodriguez-Feo and E. Garcia-Colis, Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats effect of the alpha1-receptor blocker doxazosin, J. Hypertens. 20 (2002) 463-470.10.1097/00004872-200203000-0002211875314
- R. Sharma, S. Kumar and H. K. Pujari, Reaction of 3,4,5,6,7,8-hexahydro-4-phenylquinazoline-2-thione with chloroacetic acid, Indian J. Chem. 30B (1991) 425-426.